← All trials
NCT05519254
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2023
- Primary completion
- Jul 31, 2026
- Completion date
- Dec 31, 2026
- First posted
- Aug 29, 2022
- Last posted
- Aug 29, 2022
- Enrollment
- 150
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of WashingtonLead sponsor
- National Institutes of Health (NIH)Collaborator
- University of WashingtonOverall official - principal investigator
- University of WashingtonReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.